Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)
Young Kwang Chae(Johns Hopkins University), Marcelo Cruz(Alliance for Clinical Trials in Oncology), Sarita Agte(Northwestern University), Wooyoung M. Choi(Northwestern University), Kyoungmin Lee(Ulsan College), Jonathan F. Anker(Northwestern University), Taeyeong Ko(Northwestern University), Sangmin Chang(Northwestern University), Wade T. Iams(Centerstone)
Cited by 258
Related Papers
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
|Journal for ImmunoTherapy of Cancer|2018|468
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459
Immunotherapeutic approaches for small-cell lung cancer
|Nature Reviews Clinical Oncology|2020|346